Our transwell experiment demonstrated that SLC39A1 deletion significantly reduced the invasion and migration in vitro, while the in vivo SLC39A1 expression levels are no significant difference between metastatic and nonmetastatic HCC patients. The gene discussed is SLC39A1; the disease is hepatocellular carcinoma.